27.05.2015 • News • Dede Willams • Catalysis & Catalysts • superabsorbent polymers

Nippon Shokubai to Upgrade Antwerp Acrylics Output

Japanese catalyst and superabsorbent polymer producer Nippon Shokubai has earmarked €350 million for the expansion of its production facilities for its super absorbers and construction of an acrylic acid plant at Antwerp, Belgium.

The planned expansion adding 100,000 t/y is due to start up in May 2018, nearly tripling the current 60,000 t/y capacity at the site.

Overall, the project will lift Nippon Shokubai's global super absorbers and acrylic acid capability to 710,000 t/y and 880,000 t/y respectively.

The Japanese producer is also planning to build a new 50,000 t/y plant for super absorbers at Himeji, Japan, which is due to be completed in June 2016.

Nippon Shokubai estimates steady demand for the absorbent polymers used in disposable diapers, in particular in Central and Eastern Europe.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Top-Feature

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.